Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
So what: The company gave a presentation at the JP Morgan Healthcare Conference yesterday. While there wasn't any bad news, investors didn't walk away feeling impressed. After the presentation, JP Morgan reiterated its "neutral" rating and gave the stock a $30 price target.
Now what: Thoratec has steadied somewhat since it first hit our plunged list nearly two months ago. JP Morgan analysts may have said it best when they said there are "many irons in the fire, but they're all going to take a while to heat up." I wouldn't panic over this move today, but I will keep a close eye on advancements and slip-ups in the product pipeline going forward.
Interested in more info on Thoratec? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.